Drugmakers expected to spend more on DTC ads this year

03/4/2013 | Pharmalot.com

Eli Lilly & Co.'s antidepressant Cymbalta, Pfizer's pain drug Celebrex and GlaxoSmithKline's chronic obstructive pulmonary disorder drug Advair were the most heavily promoted therapies last year, according to market research firm Cegedim Strategic Data. Overall promotional spending in the U.S. was 8% lower than in 2011, but spending on nervous system, cardiovascular, and alimentary tract and metabolism drugs showed little change. CSD's business development director said he expects to see more direct-to-consumer advertising this year.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA